New Patch Will Provide Low-Dose Estrogen Combined Hormonal Contraceptive Option
Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS)
3 Healthcare Stocks We Keep Off Our Radar
Viatris is scheduled to report its second-quarter results next month, with Wall Street expecting earnings per share to remain roughly unchanged from a year ago.
3 Unpopular Stocks We’re Skeptical Of
PITTSBURGH , July 1, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report second-quarter 2026 financial results on Thursday, August 6,...
VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well Tolerated
Viatris has outperformed its industry peers over the past year, and Wall Street appears optimistic about the stock.
1 Cash-Producing Stock with Exciting Potential and 2 Facing Headwinds
Zoetis has underperformed its industry peers over the past year, yet Wall Street remains optimistic about the stock.